Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfuvirtide (T-20) plus Optimized Background Regimen in Treatment-Experienced HIV-1
NCT00021554Phase 3Completed
- Sponsor
- Roche
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of enfuvirtide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Roche. Primary endpoint: Change in HIV-1 RNA at 24 weeks. Status: completed.
02
Drugs
enfuvirtide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00021554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021554.